Comparing the current results to its competitors, Quidelortho reported Revenue increase in the 2 quarter 2026 by 2.77 % year on year. The revenue growth was below Quidelortho's competitors' average revenue growth of 4.18 %, achieved in the same quarter.
Quidelortho's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development and marketing of in vitro diagnostic (IVD) products, characterized by rapid innovation, product development, regulatory clearance, and commercial introduction of new technologies. In the rapid diagnostic market, key competitive factors include convenience, speed to result, specimen flexibility, product menu, clinical needs, price, reimbursement levels, product performance, customer service, distribution, advertising, promotion, and brand recognition. In the central laboratory market, competition focuses on price, product performance, reimbursement, compatibility with specimen procurement methods, and manufacturing products suitable for high-volume laboratory workflows. The company competes globally with several principal competitors, including Abbott Laboratories, Bio-Rad, bioMérieux, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation, and Wermerson Immuncor, some of which have substantially greater financial, marketing, and other resources. The company emphasizes customer-centric decision making to support sustained and profitable growth.
May 16, 2024
By CSIMarket.com Reporters San Diego, CA - In a strategic move to bolster its supply chain infrastructure and enhance customer satisfaction, QuidelOrtho Corporation (Nasdaq: QDEL) has announced the launch of a state-of-the-art distribution center in Pedricktown, New Jersey. Known for their innovative diagnostic healthcare solutions, QuidelOrtho is augmenting their distribution capabilities with this new facility to foster greater operational resilience and efficiency.This initiative represents the corporation s second major distribution hub within the United States, underscoring QuidelOrtho s dedication to advanced logistical frameworks. By partnering with a third-party logistics provider, QuidelOrtho is n...
May 2, 2024
The big screen of corporate litigation has added yet another act to its unfolding drama. QuidelOrtho Corporation (NASDAQ: QDEL), a prominent player in the healthcare industry, finds itself in a tightening legal bind. Two renowned investor law firms - Pomerantz LLP and the Rosen Law Firm - have jumped into the arena, wielding class-action lawsuits against the corporation for allegedly circulating misleading business information. Pomerantz LLP cast the opening move in this sequence of legal salvos. On May 2, 2024, the law firm revealed the filing of a class-action suit, a legal maneuver used when a group of plaintiffs with similar grievances sues a defendant collectively. Pomerantz s allegations against Quidel...
April 27, 2024
In a recent announcement, Rosen Law Firm has urged investors who purchased common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022, and April 1, 2024, to seek legal counsel before the lead plaintiff deadline of June 11, 2024. This development comes as the firm represents the investors in a securities class action against QuidelOrtho Corporation. Let us analyze the key facts surrounding this lawsuit and its potential implications.Background:QuidelOrtho Corporation, a prominent medical diagnostic testing company, has encountered legal troubles stemming from alleged misconduct during the Class Period, which ran from February 2022 to April 2024. The securities class action lawsuit allege...
March 7, 2024
In recent news, the highly reputable law firm, Rosen Law Firm, has urged investors of QuidelOrtho Corporation (NASDAQ: QDEL) to participate in an ongoing securities class action investigation. The investigation aims to determine if QuidelOrtho has potentially provided misleading business information, which may have caused significant harm to shareholders. This article delves into the details of the case, exploring the facts and assessing the potential impact on the company.Background:Rosen Law Firm, renowned for its expertise in safeguarding investor rights globally, has initiated a probe into QuidelOrtho Corporation. The investigation focuses on potential securities claims arising from allegations of materi...
Biomerica Inc operates as a medical diagnostic and consumer healthcare company. It focuses on developing, manufacturing, and distributing innovative diagnostic products and tests, catering to both healthcare professionals and consumers worldwide.
Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.
Orasure Technologies Inc's business model revolves around the development, manufacturing, and distribution of innovative diagnostic products, primarily in the field of oral fluid diagnostics.
Hologic Incs business model focuses on developing and commercializing medical technologies and diagnostic products, primarily dedicated to womens healthcare. Their offerings include innovative solutions for breast and skeletal health, gynecological health, and surgical products, aiming to improve patient outcomes and enhance healthcare practices.
Sources:
Quidelortho Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quidelortho Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
